Supplementary Figure S1 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer

Key Points

• MAIN FINDING: Tifcemalimab and toripalimab may enhance progression-free survival in advanced lung cancer.
• KEY EVIDENCE: Kaplan-Meier estimates showed significant survival differences for squamous and adenocarcinoma NSCLC.
• APPROACH: The study utilized a Phase I/II design focusing on previously treated lung cancer patients.
• SIGNIFICANCE: Results suggest that targeted therapies against lymphocytes could provide new treatment strategies for lung cancer.